Market Exclusive

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 20, 2018, Ionis Pharmaceuticals, Inc. (the “Company”) announced that, effective January 2020, the Company’s founder and chief executive officer, Stanley T. Crooke, M.D., Ph.D., will transition from chief executive officer to executive chairman of the Company’s board of directors (the “Board”). Dr. Crooke will remain active in the Company, providing strategic advice and participating in the Company’s scientific activities. The Board has selected Brett P. Monia, Ph.D., Ionis’ chief operating officer and a founder of the Company, to serve as chief executive officer beginning in January 2020.

A copy of the press release announcing this transition plan is included with this report as exhibit 99.1 and incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

99.1

Press Release dated December 20, 2018.

IONIS PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis Announces Plans for Management Transitions in 2020 Carlsbad,…
To view the full exhibit click here

About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Exit mobile version